Scandinavian CDG-Ia patients:: genotype/phenotype correlation and geographic origin of founder mutations

被引:32
作者
Erlandson, A
Bjursell, C
Stibler, H
Kristiansson, B
Wahlström, J
Martinsson, T [1 ]
机构
[1] Sahlgrenska Univ Hosp E, Dept Clin Genet, S-41685 Gothenburg, Sweden
[2] Karolinska Hosp, Dept Neurol, S-10401 Stockholm, Sweden
[3] Sahlgrenska Univ Hosp E, Dept Pediat, S-41685 Gothenburg, Sweden
关键词
D O I
10.1007/s004390100489
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Congenital disorders of glycosylation type Ia, (previous name carbohydrate-deficient glycoprotein syndrome type Ia; CDG-Ia) is an inherited disorder of the glycosylation of certain glycoproteins. The defect is caused by mutations in the phosphomannomutase 2 (PMM2) gene located in chromosome region 16p13. The purpose of this study was twofold: (1) to investigate the possible correlation between certain genotypes and the phenotype of the patients and their PMM activity, and (2) to study further the founder origin of the Scandinavian mutations. Sixty-four CDG-Ia patients were studied. Regardless of mutation combination, the patients showed the basic neurological symptoms associated with CDG-Ia. However, patients carrying the mutation 548T-->C had less severe disease, e.g., no pericardial effusions, malnutrition, or clinical coagulation disturbances. Liver dysfunction and peripheral neuropathy were milder. In contrast, patients carrying mutation 691G-->A showed a high incidence of severe malnutrition and hepatopathy, and they had the highest mortality including affected siblings. Heterozygotes for the two most common mutations (422G-->A and 357C-->A) displayed a phenotype of variable severity sometimes leading to early death. PMM activity showed no correlation with either genotype or phenotype but was reduced in most patients. There was a pronounced geographic clustering for some of the Scandinavian mutations. For example, 548T-->C was almost exclusively found in patients stemming from southeastern parts of Sweden, whereas 26G-->A was found to cluster in a region in the most southern parts of Sweden, suggesting that these mutations originated in these two regions separately as founder mutations. The most frequent mutation (422G-->A) did not show a specific geographic focus. The widespread 422G-->A mutation is probably an older mutation, although haplotype data from intragenic polymorphisms indicate that this mutation also arose only once. The detailed information of the origin of mutations and their respective associated phenotypic pattern should enable improvements to be made regarding tools for genetic counseling and for prenatal diagnoses in CDG-Ia families.
引用
收藏
页码:359 / 367
页数:9
相关论文
共 28 条
[1]  
Aebi M, 2000, GLYCOBIOLOGY, V10, pIII
[2]  
Bjursell C, 2000, HUM MUTAT, V16, P395, DOI 10.1002/1098-1004(200011)16:5<395::AID-HUMU3>3.3.CO
[3]  
2-K
[4]   Fine mapping of the gene for carbohydrate-deficient glycoprotein syndrome, type I (CDG1): Linkage disequilibrium and founder effect in Scandinavian families [J].
Bjursell, C ;
Stibler, H ;
Wahlstrom, J ;
Kristiansson, B ;
Skovby, F ;
Stromme, P ;
Blennow, G ;
Martinsson, T .
GENOMICS, 1997, 39 (03) :247-253
[5]   Detailed mapping of the phosphomannomutase 2 (PMM2) gene and mutation detection enable improved analysis for Scandinavian CDG type I families [J].
Bjursell, C ;
Wahlström, J ;
Berg, K ;
Stibler, H ;
Kristiansson, B ;
Matthijs, G ;
Martinsson, T .
EUROPEAN JOURNAL OF HUMAN GENETICS, 1998, 6 (06) :603-611
[6]   A case of the carbohydrate-deficient glycoprotein syndrome type 1 (CDGS type 1) with normal phosphomannomutase activity [J].
Charlwood, J ;
Clayton, P ;
Johnson, A ;
Keir, G ;
Mian, N ;
Winchester, B .
JOURNAL OF INHERITED METABOLIC DISEASE, 1997, 20 (06) :817-827
[7]   A comprehensive genetic map of the human genome based on 5,264 microsatellites [J].
Dib, C ;
Faure, S ;
Fizames, C ;
Samson, D ;
Drouot, N ;
Vignal, A ;
Millasseau, P ;
Marc, S ;
Hazan, J ;
Seboun, E ;
Lathrop, M ;
Gyapay, G ;
Morissette, J ;
Weissenbach, J .
NATURE, 1996, 380 (6570) :152-154
[8]   Denaturing high-performance liquid chromatography is a suitable method for PMM2 mutation screening in carbohydrate-deficient glycoprotein syndrome type IA patients [J].
Erlandson, A ;
Stibler, H ;
Kristiansson, B ;
Wahlström, J ;
Martinsson, T .
GENETIC TESTING, 2000, 4 (03) :293-297
[9]  
HAGBERG B, 1996, HDB CLIN NEUROLOGY N, V66, P623
[10]   CARBOHYDRATE-DEFICIENT GLYCOPROTEIN SYNDROMES - PECULIAR GROUP OF NEW DISORDERS [J].
HAGBERG, BA ;
BLENNOW, G ;
KRISTIANSSON, B ;
STIBLER, H .
PEDIATRIC NEUROLOGY, 1993, 9 (04) :255-262